Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GFH312 in Healthy Subjects
NCT04676711Phase 1Completed
- Sponsor
- GenFleet Therapeutics
- Start
- Apr 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Inflammatory Disorders and peripheral artery disease (PAD) comparing GFH312 with Placebo (2 arms). Primary endpoint: Safety/Tolerability of GFH312 (adverse events) at 45 days. Started Apr 2021; status: completed.
02
Drugs
GFH312
03
Conditions
Inflammatory Disordersperipheral artery disease (PAD)
Beyond the preview
Go deeper on NCT04676711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676711.